Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury

Bierling, P., Bux, J., Curtis, B., Flesch, B., Fung, I., Lucas, G., Macek, M., Muniz-Diaz, E., Porcelijn, I., Reil, A., Sachs, U., Schuller, R., Tsuno, N., Uhrynowska, M., Urbaniak, S., Valentin, N., Wikman, A. and Zupanska, B. (2009) Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sanguinis, 96 3: 266-269. doi:10.1111/j.1423-0410.2008.01144.x


Author Bierling, P.
Bux, J.
Curtis, B.
Flesch, B.
Fung, I.
Lucas, G.
Macek, M.
Muniz-Diaz, E.
Porcelijn, I.
Reil, A.
Sachs, U.
Schuller, R.
Tsuno, N.
Uhrynowska, M.
Urbaniak, S.
Valentin, N.
Wikman, A.
Zupanska, B.
Title Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury
Journal name Vox Sanguinis   Check publisher's open access policy
ISSN 0042-9007
1423-0410
Publication date 2009-04
Year available 2008
Sub-type Article (original research)
DOI 10.1111/j.1423-0410.2008.01144.x
Volume 96
Issue 3
Start page 266
End page 269
Total pages 4
Place of publication Oxford, United Kingdom
Publisher Wiley-Blackwell Publishing
Language eng
Formatted abstract
Background Transfusion-related acute lung injury (TRALI) is currently one of the most common causes of transfusion-related major morbidity and death. Among the many TRALI mediators, leucocyte antibodies have been identified as important triggers of severe TRALI.
Study Design and Methods These recommendations were compiled by experts of the ISBT Working Party on Granulocyte Immunobiology, based on the results obtained in eight international granulocyte immunology workshops, their personal experiences and on published study results.
Results Leucocyte antibody screening has to include the detection of human leucocyte antigen (HLA) class I, class II and human neutrophil alloantigen antibodies using established and validated techniques. HLA class I antibody detection should be restricted to antibodies clinically relevant for TRALI. To avoid unnecessary workload, TRALI diagnosis should be assessed by consultation with the reporting clinician and thorough exclusion of transfusion-associated circulatory overload/cardiac insufficiency. In patients diagnosed with TRALI having donors with detectable leucocyte antibodies, evidence of leucocyte incompatibility should be provided by either cross-matching or typing of patient for cognate antigen.
Conclusion Leucocyte antibody screening for the immunological clarification of TRALI cases as well as for identification of potentially alloimmunized blood donors is feasible and can be performed in a reasonable and quality assured manner. This practice can contribute to the prevention of antibody-mediated TRALI.
Keyword TRALI
HNA
Leucocyte antibody detection
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Article first published online: 29 DEC 2008

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 40 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 46 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 22 Sep 2010, 09:45:14 EST